Breaking News

The ethical way to develop psychedelic medicines; confronting head-on diversity-defeating clinical trial efforts; & overriding IP rights

  

 

First Opinion

Though the dog days of summer may have come early, First Opinion authors continued to tackle topics ranging from waiving intellectual property to the ethical way to develop psychedelic medicines and confronting head-on diversity-defeating clinical trial efforts. You can read them all here. If you have an idea for an essay, or want to submit one you've written, please send it to first.opinion@statnews.com.

WTO: Don't make a bad situation worse by granting intellectual property waivers for Covid-19 therapeutics and diagnostics

By Kenneth E. Thorpe

SAUL LOEB/ via Getty Images

The WTO already suspended patent protections for Covid vaccines. They shouldn't agree to waivers on therapeutics and diagnostics too.

Read More

Working with Indigenous allies is the ethical way to develop psychedelic-based pharmaceuticals

By Jeeshan Chowdhury

Adobe

Indigenous peoples pioneered the use of psychedelics. They should benefit from the rush to make and sell psychedelic pharmaceuticals.

Read More

I learned up close and personal about the necessity of improving diversity in clinical trials

By Quita Highsmith

Expanding the diversity of clinical trials is needed for many reasons, from improving the safety of new drugs to ensuring fairness.

Read More

The Morris ALS Principles: A model for empowering all disease communities

By Irene Shapiro

LM Otero/AP

The Morris ALS Principles can serve as a guide for any disease community seeking to improve partnerships with its various stakeholders.

Read More

STAT+: How to close biopharma's data science and engineering skills gap

By Sajith Wickramasekara

Business Wire / AP Photo

Biopharma companies are competing with tech giants to recruit data scientists and engineers. Here's how they can succeed.

Read More

The future of health care is here. When will it be everywhere?

By Pratap Khedkar

Yirmiyan Arthur/AP Photo

Health care innovations grab headlines but won't benefit the millions who need them without collective action to deliver them at scale.

Read More

The FDA needs to get ready to evaluate synthetic cells, the next generation of therapeutics

By Kira Sampson and Carlise Sorenson and Kate Adamala

Jacquelyn Martin/AP

Synthetic cells represent the next generation of therapies. The FDA needs to start developing a regulatory framework for them.

Read More

Demanding more impact from impact litigation: lessons to be learned from multi-state opioid settlements

By Reuben Guttman and Liza Vertinsky

Seth Wenig/AP

The massive opioid-related settlements won by state Attorneys General should be industry-changing events. Secrecy will thwart that.

Read More

Clinician-administrator relationships are 'on life support.' Here's how to heal them

By Christine Bechtel and Lois Frankel and Jennifer Sweeney

Manu Fernandez/AP

Health system and hospital leaders feel as isolated and frustrated as clinicians. Clinician-administrator relationships must be improved.

Read More

Value-based payment has produced little value. It needs a time-out

By Kip Sullivan and Ana Malinow and Kay Tillow

Adobe

Billions of dollars have been spent on value-based payment programs that yielded little improvement in health or lower health care costs.

Read More

A better understanding of human diversity is needed to equitably advance precision medicine

By David Reese and Kári Stefánsson

Adobe

Increasing genetic diversity in global databases and biobanks is essential to advancing the field of precision medicine.

Read More

Sunday, July 31, 2022

STAT

Facebook   Twitter   YouTube   Instagram

1 Exchange Pl, Suite 201, Boston, MA 02109
©2022, All Rights Reserved.
I no longer wish to receive STAT emails
Update Email Preferences | Contact Us | View In Browser

No comments